Black Diamond Therapeutics FY2025: net income $22.4M; cash $128.7M; silevertinib milestones Q2 2026

Black Diamond Therapeutics, Inc.

Net income of $22.4M for FY2025 vs net loss $69.7M in 2024; Q4 net loss $15.1M.
Cash, equivalents, investments $128.7M at Dec 31, 2025, funding operations into 2H 2028.
Silevertinib Phase 2 NSCLC update with preliminary DOR/PFS expected Q2 2026; randomized GBM trial to start Q2 2026.
R&D expenses $33.6M in FY2025, down 34% YoY due to restructuring and focus on silevertinib.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Black Diamond Therapeutics, Inc. reported the fourth quarter of 2025 results: net income Net loss for the fourth quarter of 2025 was $15.1 million.

Period: the fourth quarter of 2025
Net income: Net loss for the fourth quarter of 2025 was $15.1 million
Result: reported results

Exact text from the filing

Net loss for the fourth quarter of 2025 was $15.1 million, as compared to $16.0 million for the same period in 2024.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Black Diamond Therapeutics, Inc. reported the year ended December 31, 2025 results: net income Net income for the year ended December 31, 2025 was $22.4 million compared to a net loss of $69.7 million for the year e.

Period: the year ended December 31, 2025
Net income: Net income for the year ended December 31, 2025 was $22.4 million compared to a net loss of $69.7 million for the year e
Result: reported results

Exact text from the filing

Net income for the year ended December 31, 2025 was $22.4 million compared to a net loss of $69.7 million for the year ended December 31, 2024.

View on SEC.gov

Browse all earnings releases →

Black Diamond Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001701541-26-000008

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.